Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Dow JonesApr 11 16:23 ET
Promising Preclinical Alzheimer's Candidate and Diverse Pipeline Bolster Hoth Therapeutics' Buy Rating
TipRanksApr 5 06:26 ET
Express News | HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
Moomoo 24/7Apr 5 06:15 ET
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Dow JonesApr 2 09:13 ET
Express News | EF Hutton Maintains Buy on Hoth Therapeutics, Raises Price Target to $7
Moomoo 24/7Apr 2 09:03 ET
Hoth Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 400% EF Hutton $6.5 → $7 Maintains Buy 02/05/2024 185.71% HC Wainwright & Co. → $4 Initiates Co
BenzingaApr 2 09:01 ET
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the...
PR NewswireMar 27 14:00 ET
Express News | Hoth Therapeutics' Merveille.ai Subsidiary Files Patent For Obesity Treatment And Begins Preparatory Steps For Clinical Trials; Merveille.ai Also Joins Nvidia Developer Program
Moomoo 24/7Mar 27 08:28 ET
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its...
PR NewswireMar 27 08:27 ET
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
Yahoo FinanceMar 20 05:38 ET
Hoth Stock Rallies 24% on Preclinical Alzheimer's Data
Seeking AlphaMar 19 10:32 ET
Hoth Therapeutics Shares Soar on Positive Data From Alzheimer's Study
Shares of Hoth Therapeutics soared after the company announced positive data in a completed pre-clinical study of its Alzheimer's Disease therapeutic HT-ALZ.
WSJMar 19 10:15 ET
Graphite Bio, SCWorx, Acurx Pharmaceuticals Among Healthcare Movers
Seeking AlphaMar 19 10:00 ET
Express News | Hoth Therapeutics Shares Are Trading Higher After the Company Announced Pre-clinical Research Showcasing the Potential of HT-ALZ in Alzheimer's Disease
Moomoo 24/7Mar 19 09:13 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersOntrak (NASDAQ:OTRK) shares rose 173.2% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $14.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN) shares rose 97.46% t
BenzingaMar 19 09:05 ET
Market-Moving News for March 19th
CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-E
BenzingaMar 19 08:41 ET
Hoth Therapeutics: Pre-clinical Research Shows HT-ALZ's Profound Impact On Alzheimer's Pathology
RTTNewsMar 19 08:41 ET
Express News | Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer's Disease
Moomoo 24/7Mar 19 08:22 ET
Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer's Disease.
Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer's Disease.
BenzingaMar 19 08:22 ET
Hoth Therapeutics Announces Data In Completed Study Of Alzheimer's Disease Pre-Clinical Treatment With HT-ALZ
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc.
BenzingaMar 19 08:22 ET
No Data
No Data